What You'll Learn
Table of Contents
Why Weight And Sleep Apnea Are Connected
Obstructive sleep apnea happens when the upper airway collapses repeatedly during sleep. Breathing stops for seconds at a time, oxygen falls, and the brain surfaces briefly to restart it — often hundreds of times a night, usually without the person remembering any of it.
Excess weight contributes in two ways: fat deposited around the neck and pharynx narrows the airway, and abdominal weight reduces lung volume, which makes the airway easier to collapse.
Which is why a drug producing substantial weight loss was worth testing here at all. The mechanism is not mysterious — it is the same mechanism as any weight loss, arriving faster.
What The Trial Found
Two randomised, double-blind, placebo-controlled trials ran in parallel for 52 weeks, in adults with moderate-to-severe obstructive sleep apnea and obesity. One enrolled people not using PAP therapy; the other enrolled people already using it and continuing throughout.
In participants not using PAP, the apnea-hypopnea index fell by 25.3 events per hour on tirzepatide against 5.3 on placebo — a treatment difference of 20.0 events per hour (95% CI −25.8 to −14.2, p < 0.001). In participants already using PAP, the fall was 29.3 versus 5.5 events per hour, a difference of 23.8 (95% CI −29.6 to −17.9, p < 0.001). Body weight fell 17.7% and 19.6% in the two tirzepatide groups, against 1.6% and 2.3% on placebo.
Read the trial on PubMed ↗Bottom line: These were double-blind and placebo-controlled, which is a stronger design than most of the evidence quoted about these medications. The effect is real and it is large.
What Twenty Events An Hour Actually Means
The apnea-hypopnea index counts breathing interruptions per hour of sleep. It is the number used to grade severity, and the conventional bands are roughly 5 to 15 for mild, 15 to 30 for moderate, and above 30 for severe.
So a reduction of 20 to 24 events per hour is not a marginal improvement. For someone starting in the severe band it is potentially the difference between severe and mild.
Two things to hold alongside that.
These are group means. Individual responses varied considerably, as they do with the weight loss itself. The average describes the trial, not a person.
The index is not the whole picture. It counts events. It does not capture how long oxygen stayed low or how someone actually feels the next day — though the trial did also report improvements in hypoxic burden and in sleep-related patient-reported outcomes.
Does This Replace CPAP?
The trial does not say that, and neither will this page.
Notice how the second trial was designed: participants continued their PAP therapy throughout, and the drug was tested on top of it. That is the opposite of a study asking whether the machine can be dropped.
What the two arms together support is narrower and still useful. The medication reduced apnea events both in people who could not or would not use PAP, and in people already using it. Those are two different clinical situations, and neither of them is an instruction to stop.
Important: Do not stop or reduce PAP therapy because your weight has fallen or because you feel better rested. Whether treated sleep apnea has actually improved is decided by a repeat sleep study, not by how you feel — and untreated obstructive sleep apnea carries cardiovascular and daytime-safety risks that are not worth guessing about. That is a conversation with the clinician managing it.
What Participants Reported
The adverse events were the ones familiar from every other trial of these drugs — mostly gastrointestinal, and more common on tirzepatide than on placebo:
- Diarrhoea — 21–26%
- Nausea — 22–25%
- Vomiting — 9–18%
- Constipation — 15–16%
Our side effects guide covers what to expect and when each of these usually settles.
The Question This Trial Also Did Not Ask
Participants lost 17.7% and 19.6% of body weight. That is the mechanism by which the apnea improved.
As with every trial on this site, the reported figure is total body weight. What that weight was made of was not the question being asked.
It matters here for a specific reason. Obstructive sleep apnea is over-represented in older adults — the group in whom lean tissue is hardest to rebuild. Losing a fifth of your body weight is the treatment. Losing a disproportionate share of it as muscle is a separate problem, and this trial was not designed to detect it.
The levers are the same as everywhere else on this site: protein intake and resistance training.
